✦ LIBER ✦

Preliminary Results of an Open Label Study of Heart Rate Variability Biofeedback for the Treatment of Major Depression

✍ Scribed by Maria Katsamanis Karavidas; Paul M. Lehrer; Evgeny Vaschillo; Bronya Vaschillo; Humberto Marin; Steven Buyske; Igor Malinovsky; Diane Radvanski; Afton Hassett

Publisher: Springer
Year: 2007
Tongue: English
Weight: 334 KB
Volume: 32
Category: Article
ISSN: 1090-0586
DOI: 10.1007/s10484-006-9029-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label study of escitalopram (Lex

An open-label study of escitalopram (Lexapro®) for the treatment of ‘Depression of Alzheimer's disease’ (dAD)

✍ V. Rao; J. R. Spiro; P. B. Rosenberg; H. B. Lee; A. Rosenblatt; C. G. Lyketsos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 2 views

## Abstract ## Background Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. ## Methods This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8‐week, open‐label treatme

Olanzapine augmentation of milnacipran f

Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study

✍ Shuken Boku; Takeshi Inoue; Hiroshi Honma; Shigehiro Matsubara; Shin Nakagawa; T 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Objective Olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment‐resistant depression (TRD). However, studies of olanzapine augmentation of other antidepressants are few. We investigated the efficacy and safety of olanz

Extracorporeal photopheresis for the tre

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study

✍ Maria T. Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

## Background: Extracorporeal photopheresis (ecp) is effective in immune-mediated disorders. a prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ecp in patients with active crohn's disease (cd) who were refractory to or intolerant of immunosuppressants and/o

A Pilot Study on the Effects of Heart Ra

A Pilot Study on the Effects of Heart Rate Variability Biofeedback in Patients with Depression and in Healthy Subjects

✍ Martin Siepmann; Volkan Aykac; Jana Unterdörfer; Katja Petrowski; Michael Mueck- 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 255 KB

Escitalopram in the treatment of major d

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

✍ Pratap Chokka; Mark Legault 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Paroxetine in the treatment of depressed

Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study

✍ Chi-Un Pae; Yoo-Jin Kim; Wang-Youn Won; Hee-Je Kim; Seok Lee; Chang-Uk Lee; Soo- 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

## Abstract ## Objective The efficacy and tolerability of paroxetine in the treatment of depressive disorders is well known, however, its efficacy and safety for the treatment of depression in patients with cancer has been poorly studied. Therefore this study was aimed at evaluating the efficacy a